Selective Alpha1a-Adrenergic Agonists for Neurodegenerative Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with adrenergic receptors, such as neurodegenerative disorders, lack effective compounds that selectively target α1A-adrenergic receptors without significant agonism for other receptor subtypes.
Innovation Solution
Development of compounds according to specific formulas (I, II, III, IV, V, VI, VII, VIII, IX, X) that act as α1A-adrenergic receptor agonists, partial agonists, or antagonists, with a focus on selective activity to improve cardiac output and cerebral blood flow.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are designed to target adrenergic receptors, then therapeutic benefits for neurodegenerative diseases and orthostatic hypotension are achieved, but selectivity for α1A-adrenergic receptors without significant agonism for other receptor subtypes is insufficient
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (Formulas I-X) that have differentiated binding characteristics for the α1A-adrenergic receptor subtype. The compounds contain specific structural features (such as substituted phenyl rings, heterocyclic groups, and particular substitution patterns) that enable selective interaction with α1A receptors while minimizing interaction with other adrenergic receptor subtypes, thereby achieving localized specificity in a system of similar receptors
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters including substituent types (halogen, hydroxyl, cyano, nitro, amino, alkyl, alkoxy groups), their positions on the molecular scaffold, and the nature of connecting chains. These parameter variations are optimized to tune the compound's affinity and selectivity for the α1A-adrenergic receptor, transforming the molecular structure to achieve desired pharmacological properties with improved selectivity
Data Source
AI summary
The present disclosure is based at least in part on the identification of compounds that modulate adrenergic receptor and methods of using the same to treat diseases associated with an adrenergic receptor. For example, disclosed herein is a compound according to Formula (I) or an optically pure stereoisomer, pharmaceutically acceptable salt, solvate, or prodrug thereof.